BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wo JY, Mamon HJ, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Tseng YD, Napolitano BN, Ancukiewicz M, Swanson RS. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiother Oncol. 2014;110:160-164. [PMID: 24231241 DOI: 10.1016/j.radonc.2013.10.027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Parekh A, Rosati LM, Chang DT, Goodman KA, Pawlik T, Koong AC, Herman JM. Stereotactic body radiation for pancreatic cancer: results of an international survey of practice patterns. J Radiat Oncol 2017;6:273-8. [DOI: 10.1007/s13566-016-0267-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Nichols RC, Huh S, Li Z, Rutenberg M. Proton therapy for pancreatic cancer. World J Gastrointest Oncol 2015;7:141-7. [PMID: 26380057 DOI: 10.4251/wjgo.v7.i9.141] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
3 Huang L, Jansen L, Balavarca Y, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Primic-žakelj M, Zadnik V, Mägi M, Pulte D, Schrotz-king P, Brenner H. Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study: Nonsurgical therapies for PaC in Europe and USA. Int J Cancer 2018;143:3227-39. [DOI: 10.1002/ijc.31628] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
4 Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15:183. [PMID: 29017581 DOI: 10.1186/s12957-017-1240-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 16.3] [Reference Citation Analysis]
5 Blair AB, Sorber R, Rozich NS, Burkhart RA. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas 2019;48:973-84. [DOI: 10.1097/mpa.0000000000001376] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-del Castillo C, Duda DG. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys 2014;89:830-8. [PMID: 24867540 DOI: 10.1016/j.ijrobp.2014.03.034] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
7 Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2019;5:1020-7. [PMID: 31145418 DOI: 10.1001/jamaoncol.2019.0892] [Cited by in Crossref: 141] [Cited by in F6Publishing: 124] [Article Influence: 141.0] [Reference Citation Analysis]
8 Russo S, Ammori J, Eads J, Dorth J. The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol. 2016;12:669-685. [PMID: 26880384 DOI: 10.2217/fon.15.335] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
9 Konski A, Meyer JE, Joiner M, Hall MJ, Philip P, Shields A, McSpadden E, Choi M, Adaire B, Duncan G, Meropol NJ, Cescon TP, Cohen SJ. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiother Oncol 2014;113:35-40. [PMID: 25441058 DOI: 10.1016/j.radonc.2014.08.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
10 Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surg Oncol Clin N Am 2017;26:431-53. [PMID: 28576181 DOI: 10.1016/j.soc.2017.01.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
11 Fukumitsu N, Okumura T, Hiroshima Y, Ishida T, Numajiri H, Murofushi KN, Ohnishi K, Aihara T, Ishikawa H, Tsuboi K, Sakurai H. Simulation study of dosimetric effect in proton beam therapy using concomitant boost technique for unresectable pancreatic cancers. Jpn J Radiol 2018;36:456-61. [DOI: 10.1007/s11604-018-0743-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sutton JM, Abbott DE. Neoadjuvant therapy for pancreas cancer: past lessons and future therapies. World J Gastroenterol. 2014;20:15564-15579. [PMID: 25400440 DOI: 10.3748/wjg.v20.i42.15564] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
13 Eskander MF, Bliss LA, Tseng JF. Pancreatic adenocarcinoma. Current Problems in Surgery 2016;53:107-54. [DOI: 10.1067/j.cpsurg.2016.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]